Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Fibritor is indicated for:
Pharmacology
Hypertriglyceridemia together with reduced HDL-C is a risk factor for Atherosclerotic Cardiovascular Disease (ASCVD). A sedentary lifestyle, a lipid-rich diet and similar factors make high triglyceride (TG) harder to control. Fibrates are considered the preferred treatment for reducing TG. They work mainly by binding to and activating peroxisome proliferator activated receptor alpha (PPARα), a nuclear receptor. But conventional fibrates have low selectivity and potency for binding to PPARα. As a result, they sometimes fail to bring TG down to the desired level, and they are often linked with various side effects. Pemafibrate is a new selective PPARα modulator, and it is strongly effective in treating hypertriglyceridemia and low HDL-C levels. Its unique Y-shaped structure lets it bind tightly to the PPARα receptor. The structure of Pemafibrate contains benzoxazole and phenoxyalkyl side-chains along with the common fibric acid group, which gives high selectivity for PPARα, strong interaction with the receptor, and maximum activation of the receptor. Thus, Pemafibrate shows over 2,500-fold greater potency for PPARα compared to conventional fibrates and gives a better therapeutic outcome.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The usual adult dose of pemafibrate is 0.1 mg taken by mouth twice daily. The doctor may adjust the dose according to the patient's age and symptoms. You can take pemafibrate with or without food.
Pemafibrate's safety in children has not been established.
Renal impairment: Use pemafibrate with caution in patients whose estimated glomerular filtration rate (eGFR) is less than 30 mg/min/1.73 m2. A lower starting dose or longer dosing intervals should be considered. The maximum dose is 0.2 mg daily.
Hepatic impairment: Use pemafibrate with caution in patients with severe hepatic disorder.
Side Effects
Pemafibrate can cause stomach and bowel upset, such as nausea, diarrhoea and abdominal pain. Jaundice, skin rashes, gallstones and myotoxicity (muscle damage) have also been reported.
Cautions & Contraindications
Warnings & Precautions
Other fibrates have been reported to raise the risk of rhabdomyolysis when given together with an HMG-CoA reductase inhibitor (statin), especially if the patient already has a muscle disease. So Pemafibrate should be used with caution in patients who are taking statins. Muscle toxicity should be suspected if a patient has diffuse myalgia, myositis, muscle cramps and weakness, and/or a marked rise in CK (more than 5 times the upper limit of the normal range). If this happens, treatment with Pemafibrate should be stopped. Use Pemafibrate with caution in patients who have a hepatic disorder or a history of one. Abnormal liver function tests may occur. The plasma concentration of Pemafibrate may also increase in patients with hepatic disorder (Child-Pugh grade A cirrhosis, etc). Liver function should be monitored periodically during treatment. Cholelithiasis has been reported, so Pemafibrate should be used with caution in patients with a history of cholelithiasis. LDL-cholesterol levels may increase, so they should be monitored periodically during treatment.
Contraindications
Pemafibrate must not be given to people with a known hypersensitivity to pemafibrate or to any of its excipients. It is also contraindicated in patients with severe hepatic disorder, Child-Pugh grade B or C cirrhosis, or biliary obstruction, and in patients with cholelithiasis. Women who are pregnant or possibly pregnant should not take it. The same applies to patients who are receiving cyclosporine or rifampicin at the same time.
Pregnancy & Breastfeeding
Pregnancy: Pemafibrate must not be used by women who are pregnant or who may be pregnant. Its safety in pregnancy has not been established.
Breast-feeding: Women who are breast-feeding should avoid Pemafibrate. If the medicine can't be avoided, breast-feeding should be stopped.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Storage
Store Pemafibrate at a temperature no higher than 30°C. Keep it away from light, and keep it out of the reach of children.
Drug Interactions
Common questions about Fibritor 0.1 mg
What is Fibritor 0.1 mg Tablet?
Fibritor 0.1 mg Tablet is a medicine that contains Pemafibrate .. It is made by NIPRO JMI Pharma Limited. It belongs to the Anti-anginal & lipid lowering drugs group of medicines.
What is Fibritor used for?
Fibritor is used for: Hyperlipidemia.
What are the side effects of Fibritor?
Pemafibrate can cause stomach and bowel upset, such as nausea, diarrhoea and abdominal pain. Jaundice, skin rashes, gallstones and myotoxicity (muscle damage) have also been reported.
Can I take Fibritor during pregnancy or while breastfeeding?
Pregnancy: Pemafibrate must not be used by women who are pregnant or who may be pregnant. Its safety in pregnancy has not been established. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Fibritor?
Store Pemafibrate at a temperature no higher than 30°C. Keep it away from light, and keep it out of the reach of children.
Can I take other medicines with Fibritor?
Some medicines can interact with Pemafibrate ., for example: Warfarin Sodium. Tell your doctor or pharmacist about every medicine you take.
Is there a cheaper medicine with the same ingredient?
Fibritor is already among the lowest-priced brands of Pemafibrate . at this strength.
Do I need a prescription for Fibritor?
Fibritor is a prescription (Rx) medicine. Take it as your doctor advises.